BusinessXeris Pharmaceuticals Announces a Formulation Development Collaboration with Asahi Kasei PharmaBy Nasdaq OMXMar 13, 2018, 9:00 PM UTC
BusinessXeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe HypoglycemiaBy Nasdaq OMXFeb 15, 2018, 10:00 PM UTC
BusinessFDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.By Nasdaq OMXFeb 8, 2018, 11:30 PM UTC
BusinessXeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board of DirectorsBy Nasdaq OMXSep 7, 2017, 8:30 PM UTC
BusinessXeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development ProgramBy Nasdaq OMXJun 16, 2017, 11:51 AM UTC
BusinessXeris Pharmaceuticals Announces Closing of $30 Million FinancingBy Nasdaq OMXMay 17, 2017, 11:00 PM UTC
BusinessXeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEOBy Nasdaq OMXJan 9, 2017, 12:00 PM UTC
BusinessXeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD MeetingBy Nasdaq OMXFeb 4, 2016, 3:22 PM UTC
